McDermott Will & Schulte has advised Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, on its €60 million financing with a €20M strategic investment from Sanofi and support from global healthcare specialists to advance genetic medicine pipeline.
The McDermott Will & Schulte team comprised:
- Emmanuelle Trombe, partner, on Life Sciences aspects
- Bertrand Delafaye, partner, Henri Nalbandyan and Agathe Bourdillon, associates, on Capital Markets aspects